60O First-in-human phase I evaluation of HCB301, a tri-specific SIRPα-PD-1-TGFβ fusion protein: Safety, pharmacokinetics, and multisystem immune activation

Read full text Summarise with VIRAT
Authors: J. Zhu, William Jeffrey Edenfield, Hongyan Tong, L. Sun, A. Liu, X. Hu, A. Yu, F. Mo, Alvin Y. Luk
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

HCB301 is an engineered tri-specific IgG4 fusion protein designed to overcome immune resistance by blocking the SIRPα-CD47 innate checkpoint, inhibiting PD-1/PD-L1-mediated T-cell suppression, and neutralizing TGFβ. This design aims to activate macrophage phagocytosis, restore T-cell effector function, and remodel immune-excluded tumor microenvironments. Preclinical studies confirmed activity across all three pathways with innate and adaptive immune activation while preserving hematologic safety.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Phagocytosis and Immune Regulation Immunotherapy and Immune Responses

Publication details

Journal / source
ESMO Open
Volume
11
Pages
106201–106201
Publication date
1 April 2026
Language
EN